Page 2 - Management of Advanced Urothelial Carcinoma: Emerging Therapies and Biomarkers
P. 2
Program Faculty
Program Scott North Srikala Sridhar
Chairs Cross Cancer Institute University Health Network
Edmonton, Alberta Toronto, Ontario
Program Peter Black Tracy Stockley
Faculty University of British Columbia University Health Network
Vancouver, British Columbia Toronto, Ontario
Pierre Karakiewicz
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec
This program is also possible by the contribution of the GURC working group, a multidisciplinary working
group who drafted a management algorithm for advanced urothelial carcinoma in 2019 that includes
st
newly approved 1 Line anti-PD-L1 therapies, emerging anti-FGFR and anti-Nectin 4 therapies and
required biomarker testing of PD-L1 expression levels and FGFR gene alterations.